Targeting c‐Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple‐negative breast cancer

Documenti analoghi

• KMT2D‐mediated H3K4me1 recruits YBX1 to facilitate triple‐negative breast cancer progression through epigenetic activation of c‐Myc
  di: Bing Yao, et al.
  Pubblicazione: (2024)
• Predictive circulating biomarkers of the response to anti‐PD‐1 immunotherapy in advanced HER2 negative breast cancer
  di: Yuhan Wei, et al.
  Pubblicazione: (2025)
• Targeting the MDK/c‐Myc complex to overcome temozolomide resistance in glioma
  di: Xiaonan Xi, et al.
  Pubblicazione: (2025)
• PCDHGB7 inhibits the progression of triple‐negative breast cancer by suppressing XRCC5/MYC‐mediated ribosome biogenesis
  di: Ming Shan, et al.
  Pubblicazione: (2025)
• Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple‐negative breast cancer patients
  di: Chiara Massa, et al.
  Pubblicazione: (2024)